Speakers
Takashi Kohno, PhD
Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center, Japan
View abstract in Invited Session 4
Biography
Dr. Takashi Kohno began his career as a researcher in the Biology Division at the National Cancer Center Research Institute (NCCRI) in 1995. He became Section Head of the Biology Division in 2000 and Chief of the Division of Genome Biology in 2011. From 2018 to 2023, he was Section Head in the Section of Data Science Strategy at the Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center. In 2023, he was appointed Director of C-CAT, where he oversees advanced cancer genomics research and therapy development. His key accomplishments include identifying RET fusion as a novel therapeutic target and implementing NCC Oncopanel, a comprehensive genomic profiling test.
Kouya Shiraishi, PhD
Department of Clinical Genomics, National Cancer Center Research Institute, Japan
View abstract in Invited Session 4
Biography
Since 2008, Dr. Kouya Shiraishi has served as a researcher and laboratory head in the Division of Genome Biology at the National Cancer Center Research Institute, where he has conducted genomic analyses of germline variants in lung cancer. In 2022, he was appointed Chief of the Department of Clinical Genomics. Through genome-wide association studies, he identified several lung adenocarcinoma susceptibility loci and characteristics of EGFR-mutation-positive lung adenocarcinoma in Asian populations. He currently conducts genomic epidemiological research that combines omics data with lifestyle information to identify high-risk groups more accurately. He also serves as a council member and associate editor of the Japanese Cancer Association and Vice Chair of the Biobank Committee at the National Cancer Center.
I-Shou Chang, PhD
National Institute of Cancer Research, National Health Research Institutes, Taiwan
View abstract in Invited Session 4
Biography
I-Shou Chang is an Investigator Emeritus at the National Institute of Cancer Research, National Health Research Institutes (NHRI), Taiwan. He earned his PhD in Mathematics from Columbia University in 1976. He was an associate professor and professor in the Department of Mathematics at National Central University, Taiwan, from 1976 to 2002, and a visiting professor in the Department of Mathematical Statistics at Columbia University from 1989 to 1990. At NHRI, he served as an investigator in the President's Laboratory and the National Institute of Cancer Research, as Director of the Department of Research Resources and Biomedical Research Resources, and as Director of the Department of Academic Planning. His research interests include cancer epidemiology, cancer risk prediction, and multi-omics studies.
Chao-Hua Chiu, MD
Taipei Medical University Hospital, Taiwan
View abstract in Invited Session 4
Biography
Dr. Chao-Hua Chiu is Professor of Medicine, Vice Superintendent at Taipei Cancer Center, and Director of the Clinical Research Center at Taipei Medical University Hospital, Taipei Medical University, Taiwan. He earned his MD from Taipei Medical University and completed dual specialty training in pulmonology and medical oncology at Taipei Veterans General Hospital. From 2006 to 2008, Dr. Chiu served as a visiting scientist in the Department of Molecular and Cellular Oncology at MD Anderson Cancer Center. He later directed the Section of Thoracic Oncology at Taipei Veterans General Hospital from 2016 to 2022 before assuming his current leadership roles at Taipei Medical University. His clinical work and research interests focus on low-dose CT lung cancer screening, targeted therapies, and clinical trials for thoracic malignancies.
Shunsuke Shiota, MMSc
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
View abstract in Invited Session 5
Biography
Shunsuke Shiota, MMSc, is a biostatistics reviewer in the Office of New Drug V at the Pharmaceuticals and Medical Devices Agency (PMDA), Japan. He is responsible for the statistical review of anticancer drug applications, with a focus on the design, analysis, and interpretation of confirmatory oncology clinical trials.